Cooper Companies Inc

Cooper Companies Inc(COO)股票分析

$57.400

+2.635 (+4.59%)收盤時

Loading chart…
最高
57.470
開盤
55.490
成交量加權均價
56.78
成交量
2.89M
市值
17.45B
最低
55.460
成交金額
163.84M
企業價值/稅息折舊攤銷前利潤(TTM)
9.85

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

AI 分析 of Cooper Companies Inc (COO)

持有

Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.

分析師評級(15)

上檔空間 +57.37%
買進
10 買進
5 持有
0 賣出
目前: 57.40
最低
73.00
平均
90.33
最高
100.00

Barclays

2026-10-06

目標價

$60

Equal Weight

Mizuho

2026-09-11

目標價

$75

優於大盤

JPMorgan

2026-09-10

目標價

$58

中性

Needham

2026-09-10

目標價

$73

買進

Citi

2026-09-10

目標價

$60

中性

估值指標

Cooper Companies Inc(COO)目前預期本益比為 11.34,5 年平均預期本益比為 22.85。

預期本益比

嚴重低估
5 年均值 P/E
22.85
目前P/E
11.34
高估
28.01
低估
17.68

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
19.29
目前EV/EBITDA
9.85
高估
45.89
低估
-7.32

預期股價營收比

嚴重低估
5 年均值 P/S
4.37
目前P/S
2.37
高估
5.31
低估
3.43

Alphio AI 對 COO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%COO

$100.88

情境價格

基

基準

基準 · 50%COO

$92.29

情境價格

悲

悲觀

悲觀 · 25%COO

$83.71

情境價格

持有 COO 的大戶

G

Generation Investment Management LLP

+ 持有COO

+11.12%

3個月報酬率

T

Trajan Wealth, L.L.C.

+ 持有COO

+6.51%

3個月報酬率

S

Sustainable Growth Advisers, LP

+ 持有COO

+5.81%

3個月報酬率

H

HBK Investments L.P.

+ 持有COO

+2.71%

3個月報酬率

S

Staley Capital Advisers, Inc.

+ 持有COO

+2.60%

3個月報酬率

H

Heartland Advisors, Inc.

+ 持有COO

+2.01%

3個月報酬率

COO 常見問題 —— 由 Alphio AI 解答

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易